Stock Scorecard
Stock Summary for Adma Biologics Inc (ADMA) - $9.33 as of 9/1/2026 8:51:56 PM EST
Total Score
12 out of 30
Safety Score
43 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ADMA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ADMA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ADMA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ADMA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ADMA (43 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ADMA
Financial Details for ADMA
Company Overview |
|
|---|---|
| Ticker | ADMA |
| Company Name | Adma Biologics Inc |
| Country | USA |
| Description | ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 9.33 |
| Price 4 Years Ago | 3.88 |
| Last Day Price Updated | 9/1/2026 8:51:56 PM EST |
| Last Day Volume | 1,756,140 |
| Average Daily Volume | 2,264,715 |
| 52-Week High | 20.46 |
| 52-Week Low | 7.21 |
| Last Price to 52 Week Low | 29.40% |
Valuation Measures |
|
| Trailing PE | 13.41 |
| Industry PE | 40.38 |
| Sector PE | 44.74 |
| 5-Year Average PE | 15.23 |
| Free Cash Flow Ratio | 15.30 |
| Industry Free Cash Flow Ratio | 37.58 |
| Sector Free Cash Flow Ratio | 35.74 |
| Current Ratio Most Recent Quarter | 6.97 |
| Total Cash Per Share | 0.61 |
| Book Value Per Share Most Recent Quarter | 1.81 |
| Price to Book Ratio | 5.20 |
| Industry Price to Book Ratio | 4.31 |
| Sector Price to Book Ratio | 8.85 |
| Price to Sales Ratio Twelve Trailing Months | 4.11 |
| Industry Price to Sales Ratio Twelve Trailing Months | 50.70 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.40 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 223,985,000 |
| Market Capitalization | 2,089,780,050 |
| Institutional Ownership | 93.26% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -52.80% |
| Annual Earnings Growth | -25.67% |
| Reported EPS 12 Trailing Months | 0.70 |
| Reported EPS Past Year | 0.33 |
| Reported EPS Prior Year | 0.63 |
| Net Income Twelve Trailing Months | 168,957,000 |
| Net Income Past Year | 146,930,000 |
| Net Income Prior Year | 197,673,000 |
| Quarterly Revenue Growth YOY | 15.90% |
| 5-Year Revenue Growth | 64.60% |
| Operating Margin Twelve Trailing Months | -123.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 136,020,000 |
| Total Cash Past Year | 87,630,000 |
| Total Cash Prior Year | 103,147,000 |
| Net Cash Position Most Recent Quarter | -56,819,000 |
| Net Cash Position Past Year | 18,300,000 |
| Long Term Debt Past Year | 69,330,000 |
| Long Term Debt Prior Year | 72,337,000 |
| Total Debt Most Recent Quarter | 192,839,000 |
| Equity to Debt Ratio Past Year | 0.87 |
| Equity to Debt Ratio Most Recent Quarter | 0.68 |
| Total Stockholder Equity Past Year | 477,320,000 |
| Total Stockholder Equity Prior Year | 349,018,000 |
| Total Stockholder Equity Most Recent Quarter | 408,208,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 116,469,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.52 |
| Free Cash Flow Past Year | 27,821,000 |
| Free Cash Flow Prior Year | 110,097,000 |
Options |
|
| Put/Call Ratio | 0.03 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.18 |
| MACD Signal | 0.23 |
| 20-Day Bollinger Lower Band | 7.07 |
| 20-Day Bollinger Middle Band | 9.04 |
| 20-Day Bollinger Upper Band | 11.00 |
| Beta | 0.77 |
| RSI | 51.51 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 13.39 |
| 200-Day SMA | 10.94 |
System |
|
| Modified | 9/1/2026 4:33:21 PM EST |